| Entry |
|
|---|
| Name |
Uridine triacetate (USAN/INN);
Xuriden (TN)
|
|---|
| Product |
|
|---|
| Formula |
C15H18N2O9
|
|---|
| Exact mass |
370.1012
|
|---|
| Mol weight |
370.3114
|
|---|
| Structure |
   |
|---|
| Simcomp |
 |
|---|
| Remark |
|
|---|
| Efficacy |
Antidote (5-fluorouracil) |
|---|
| Disease |
|
|---|
| Comment |
Antidote for 5-fluorouracil toxicity due to overdose or impaired elimination, treatment of mitochondrial diseases
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
A16 OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
A16AX Various alimentary tract and metabolism products
A16AX13 Uridine triacetate
D09985 Uridine triacetate (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
New Molecular Entity and New Therapeutic Biological Product Approvals
D09985
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D09985
 |
|---|
| Other DBs |
|
|---|
| LinkDB |
 |
|---|
| KCF data |
ATOM 26
1 C1y C 26.0045 -19.0270
2 N4y N 27.5752 -18.5986
3 O2x O 24.8621 -18.2417
4 C1y C 25.5761 -20.4549
5 C8y C 28.7889 -19.2412
6 C8x C 27.5752 -17.1707
7 C1y C 23.7198 -19.0984
8 C1y C 24.1482 -20.4549
9 O7a O 26.4328 -21.5972
10 N4x N 30.0026 -18.5986
11 O5x O 28.7889 -20.6691
12 C8x C 28.7889 -16.4568
13 C1b C 22.3633 -18.6700
14 O7a O 23.2914 -21.5972
15 C8y C 30.0026 -17.1707
16 O7a O 21.2924 -19.5268
17 O5x O 31.2877 -16.4568
18 C7a C 26.4328 -23.0252
19 O6a O 25.3619 -23.5963
20 C1a C 27.6465 -23.7391
21 C7a C 20.0786 -18.8128
22 C1a C 18.8649 -19.5268
23 O6a O 20.0786 -17.5277
24 C7a C 23.2914 -22.9972
25 C1a C 22.0792 -23.6971
26 O6a O 24.5321 -23.7130
BOND 27
1 1 2 1 #Up
2 1 3 1
3 1 4 1
4 2 5 1
5 2 6 1
6 3 7 1
7 4 8 1
8 4 9 1 #Down
9 5 10 1
10 5 11 2
11 6 12 2
12 7 13 1 #Up
13 8 14 1 #Down
14 10 15 1
15 13 16 1
16 15 17 2
17 7 8 1
18 12 15 1
19 9 18 1
20 18 19 2
21 18 20 1
22 21 16 1
23 21 22 1
24 21 23 2
25 14 24 1
26 24 25 1
27 24 26 2
|
|---|
